Veeva (VEEV) Expands with Astellas and Sarah Cannon in Global CRM and Oncology Trials

Veeva Systems Inc. (NYSE:VEEV) ranks among the best cloud stocks to buy according to Wall Street analysts. Veeva Systems Inc. (NYSE:VEEV) appears to be expanding its network this year in the form of high-impact partnerships. In June, the company declared that pharmaceutical giant Astellas would adopt Veeva Vault CRM as the industry standard for commercial operations across the globe, including a customized version for China. The goal of the collaboration is to employ Veeva’s data and technological solutions to improve Astellas’ commercial agility and execution capabilities.

Veeva’s Vault CRM is designed to meet the diverse legal and business needs of different countries. The software is a component of the Vault CRM Suite, which attempts to improve commercial performance by facilitating communication between the medical, marketing, and sales teams.

The same month, Veeva Systems Inc. (NYSE:VEEV) launched its Clinical Platform across more than 200 oncology research sites in collaboration with the Sarah Cannon Research Institute, a significant endorsement of its technology for expediting cancer trials.

Veeva Systems Inc. (NYSE:VEEV) is a healthcare software services provider that aids organizations in managing drug development, customer engagement, and a variety of other operations. The company added a new cloud platform in September 2023 intended to assist pharmaceutical manufacturers in managing their supply chains and production.

While we acknowledge the potential of VEEV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.